Aiadvertising Inc (OTCMKTS: AIAD) is making an explosive move up the charts well into copper land after reversing off $0.0069 lows. AIAD is the new ticker for CLWD which has a history of making moves skyrocketing from under a penny to highs of $0.18 per share in February 2021. The Company has been making moves in the rapidly emerging AIaaS category of Advertising, an enormous market expected to reach $21 billion in 2023 according to AIAD CEO Andrew Van Noy who also recently said: “if we can capture a mere 1% of that market, this is a multi-billion-dollar business. The contracts we have signed so far this year are across a wide range of industries, and the success of our sales team in closing these deals is very encouraging.”
Indead, AiAdvertising is making a lot of progress and recent clients include Petco, ADT, John Deere, Panasonic, Jared, Under Armour, Movado, Karen Millen, Home Depot Foundation, Kay Jewelers, Prince, and Career Builders, Desert Mountain, Berry Petroleum and Holt Kat just to name some of the more recognizable brands. Aiadvertising is successfully executing on its transition from operating as an agency with inconsistent and unpredictable revenue to an integrated AI-as-a-Service (AIaaS) platform solution with scalable and predictable, monthly, recurring revenue. The Company has signed nine new Platform License Agreements since the beginning of the year which totals more than $5 million in annualized revenue.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Aiadvertising Inc (OTCMKTS: AIAD) is an artificial intelligence (AI) and machine learning (ML) data science and technology company. The Company’s flagship solution, the Ai Ad Platform, is the digital ad industry’s first cloud-hosted ad management platform that leverages AI, enabling marketers to eliminate waste, predict winning creative, dynamically scale creative, generate more leads, acquire more customers, and increase ROI.
AiAdvertising’s primary focus is to disrupt the digital advertising world by offering a solution that harnesses the power of artificial intelligence (AI) to enable marketers to increase productivity, efficiency and performance. The Company is looking to partner with marketers who are looking to challenge the “status quo” and empower them with a unified solution to eliminate wasted spend, replace human guesswork with AI-enabled predictions to provide accountability and provide transparency to their marketing budget.
The AIAD Platform harnesses the power of machine learning and artificial intelligence to eliminate guesswork, predict what works, and prove advertising’s impact on financial results. Key features of our platform include:
Alignment – We start with the end in mind and use a comprehensive discovery process to outline goals and key performance indicators (KPIs) to connect them to revenue targets. By aligning on the desired outcomes, our platform renders marketing and content calendars built upon the defined goals and objectives.
Insights – AI Data Services inventories and aggregates data from all of a client’s tools, such as customer relationship management (CRM), sales, marketing, accounting, and customer service tools into a unified data warehouse where it is cleaned, organized, and tagged. This allows the artificial intelligence in our platform to segment customers and prospective customers by revealing patterns, signals, and insights to draw commonalities between points and grouping them into personas (fictional characters used to represent larger groups that share similarities). Once these audiences are segmented, we use unique engagement predictors leveraging psychographic models to identify motivations, behaviors, influences, and interests. These insights inform the type of creative assets these audience segments will most likely respond to. The models are leveraged to find new incremental audiences.
To Find out the inside Scoop on AIAD Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Activate – The AI platform scores clients’ existing creative assets and intelligently recommends enhancements to optimize performance. The Company’s AI leverages the audience personas of who will see the ads to accurately personalize and predict more successful creative assets. This predictive engine allows clients to know the likelihood that their ad will resonate with their audiences before placing the ad. Our AI can then dynamically create hundreds or thousands of variations of highly targeted ads based on what our AI knows about the specific audience personas. Combined with our software, our teams then help our clients place these ads through the channels that will produce the highest results.
Decisions – The AiAd dashboard aggregates data from all marketing channels to connect marketing strategies to financial results. Aiadvertisingr platform continuously monitors and validates each campaign’s impact and provides recommendations to maximize their effectiveness. Leveraging machine learning, it provides ongoing analysis and optimization of behavioral profiles, creative, audience segments, and media activation. Aiadvertisingr platform empowers marketers to know what works, what doesn’t, what’s next, and why so they can make the most informed decisions.
Earlier this year AIAD formed a Master Licensing Agreement with Campaign Nucleus, LLC to leverage the Ai Ad Platform to provide persona-based dynamically created ads and creative content to Nucleus’ Customers as well as activating omnichannel digital advertising. Founded and created by Brad Parscale, former Digital Director and Campaign Manager for President Donald J. Trump, Campaign Nucleus is an AI-based digital platform that provides center-right candidates, organizations and corporations a centralized ecosystem to not only curate actionable data, but also build political movements through accountability, analysis and action. Parscale’s experience as a developer, marketer and political consultant has shaped Campaign Nucleus, which can help win elections and drive influence.
On April 8 AIAD reported it has entered into a License and Development Agreement with Genus AI. In addition, AiAdvertising and Genus AI will co-develop the automation of predictive video image generation leveraging user generated content from influencers. This will be activated on TikTok and YouTube, which are currently the fastest growing channels of digital media ad spend. This co-development will include the application of new deep learning models optimized for handling user-generated content.
AiAdvertising CEO Andrew Van Noy stated: “The partnership announced today will lead to the full integration of Genus AI’s technology into our platform, enabling us to provide unprecedented levels of micro-audience targeting of video-based creative across Meta (formerly known as Facebook) and Instagram. Additionally, this partnership will enable our Ai Ad Platform to auto-create and scale recommendations on clients’ existing creative ad design. As we automate AI workflow processes and we further build out our digital media libraries, we see a clear pathway to offering clients fully-automated, synthesized video creative.”
Currently trading at a $13,268,783 market valuation AIAD has 1,134,084,046 shares outstanding. AIAD is “pink current” and an SEC filer and are eligible to up list to OTCQB. The Company recently filed its 10Q at which time BMIX had $3 million in assets including $2.6 million in the treasury vs $1.8 million in liabilities. AIAD is an exciting story developing in small caps; the stock is making an explosive move up the charts well into copper land after reversing off $0.0069 lows. The Company has been making moves in the rapidly emerging AIaaS category of Advertising, an enormous market expected to reach $21 billion in 2023 according to AIAD CEO Andrew Van Noy who also recently said: “if we can capture a mere 1% of that market, this is a multi-billion-dollar business. AiAdvertising is making a lot of progress and recent clients include Petco, ADT, John Deere, Panasonic, Jared, Under Armour to name a few. The stock has a significant gap to fill from current levels back to $0.18 highs it reached in 2021 when AIAD was still trading as CLWD.We will be updating on AIAD when more details emerge so make sure you are subscribed to Microcapdaily.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
sclosure: we hold no position in AIAD either long or short and we have not been compensated for this article.
Organogenesis Holdings (NASDAQ: ORGO), a top regenerative medicine company dedicated to advanced wound care, surgical, and sports medicine solutions, gains over 30% during intraday trading and after hours combined after their latest release. According to the release, three Medicare Administrative Contractors (MACs) decided to withdraw certain coverage rules that were meant to start on October 1. These rules related to products for treating diabetic foot ulcers (DFU) and venous leg ulcers (VLU).
More Background:
Organogenesis serves a range of clients, from hospitals and wound care centers to doctors’ offices. The MACs’ initial rules, set on August 9, caused concern. They specified that covered products must be particular types of skin substitutes. Unfortunately, this excluded five products from Organogenesis, impacting their financial outlook.
Fast forward, the MACs pulled back these rules just in time, preventing potential harm to Organogenesis. Even before these rules, the company was facing challenges. In the second quarter, revenue was slightly down compared to the same period last year. Despite this, the company is doing better than the previous year in a six-month comparison.
Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Gary S. Gillheeney, Sr., the head of Organogenesis, expressed deep gratitude for the MACs and the Centers for Medicare & Medicaid Services (CMS). He praised their thoughtful consideration of stakeholder concerns and putting patients first. This decision will positively affect the lives of many.
He also thanked the stakeholders, including doctors, patient advocacy groups, and various associations. Their unified support played a vital role in challenging these rules, considering the potential harm they could cause patients. Their advocacy shed light on the possible negative health outcomes and treatment disparities, especially for those with higher rates of diabetes and related conditions. Their collective efforts made a significant difference.
We will update you on ORGO when more details emerge, subscribe to Microcapdaily to follow along!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
On September 25, 2023, Vaccitech (NASDAQ: VACC) experienced a jaw-dropping 90% surge in its stock price in just one day of trading. Now, this kind of jump usually happens when a company drops a major announcement or puts out a significant SEC filing. But, surprise, surprise—there was nothing of that sort this time .So naturally we did some digging, explored further online and guess what? Turns out retail traders were also not on a main reason for this rollercoaster ride. Curious to uncover what’s really behind this financial rollercoaster? Before we go any further, let’s get to know Vaccitech a bit better. There’s some pretty important aspects on the company you might like.
Background:
Vaccitech operates as a clinical-stage biopharmaceutical company, dedicated to discovering and developing innovative T cell immunotherapies. These therapies are crafted to leverage the immune system’s potency for treating conditions like chronic infectious diseases, cancer, and autoimmune disorders.
What sets Vaccitech apart is their distinctive, multi-platform approach, demonstrating the capacity to generate higher quantities of T cells compared to alternative technologies. This places Vaccitech in a unique position to cater to the needs of substantial, yet underserved patient populations. Their diverse clinical-stage pipeline includes potential treatments for severe diseases with limited available treatments, presenting significant public health risks.
Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Among their lead product candidates are VTP-300, an immunotherapeutic designed to contribute to a potential functional cure for chronic hepatitis B viral (HBV) infection. Additionally, VTP-200 is a non-invasive, early-stage investigational treatment targeting persistent, high-risk human papillomavirus (HPV). VTP-850 stands out as a novel T cell investigational therapy aimed at prostate cancer, while VTP-1000, a preclinical T cell therapeutic candidate, focuses on reinstating immune tolerance in celiac disease.
Vaccitech possesses well-established expertise in drug development and scientific knowledge within the immunization realm. Notably, they co-developed a COVID-19 vaccine in collaboration with the University of Oxford. As many of you know, their vaccine has been successfully approved and holds an exclusive license worldwide with AstraZeneca.
What happened:
The one and only thing that happened today was Alliance Global Partners adding coverage of Vaccitech with a favourable buy recommendation.What’s truly eye-catching are the projections made, suggesting some pretty significant upside. The average one-year price target for Vaccitech is $12.24. Forecasts within this period have a bit of a spectrum, reaching from a low estimate of $7.07 to a high of $15.75. With that said, from today’s closing price that’s nearly 400% gain.
What’s The Big Deal?:
Alliance Global Partners giving the green light to cover Vaccitech is like a thumbs-up from a respected expert. It’s like a top-tier food critic saying, “This restaurant is a must-try.”
Think of it as Vaccitech stepping into the spotlight. It’s like a talented musician getting featured on a famous music blog—suddenly, more people start paying attention.
When a big player like Alliance Global Partners says, “Hey, this stock is a good buy,” it’s like a friend recommending a must-watch movie. You’re more likely to check it out based on that suggestion.
This kind of recommendation can also affect the stock price. It’s similar to when a popular influencer talks about a cool product—lots of people want to try it.
In a nutshell, this coverage is like a stamp of approval, making Vaccitech catch the attention of more potential investors and possibly giving the stock a boost. But it’s important to mention that just because a well established financial firm gives a price target, does not mean it’s accurate. In fact, tons of these projections are made daily with many being totally off the mark. Always do your own due diligence.
We will update you on VACC when more details emerge, subscribe to Microcapdaily to follow along!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Elutia Inc (NASDAQ: ELUT) shares bolstered a whopping 33% today as the company recently shared that they’ve secured about $10.5 million in funding through a private investment round. If all the warrants are cashed in as part of this funding, the total could go up to $26.2 million.
Latest Changes:
Just last week, Aziyo Biologics changed its name to Elutia Inc. Following this change, Elutia made an announcement about selling its Orthobiologics business unit to Berkeley Biologics, a subsidiary of GNI Group Ltd. This move is set to bring in a substantial amount of cash, totalling up to $35 million for Elutia. This sum includes a notable upfront payment of $15 million, plus additional potential earnings of up to $20 million over five years. The deal is expected to be finalized in the fourth quarter of 2023.
This sale is a big step for Elutia, especially in the realm of drug-eluting biomatrix technology (DEB). Elutia is actively seeking approval from the FDA for their main product, CanGaroo RM. This product utilizes innovative biomatrix technology with antibiotics rifampin and minocycline (RM), providing long-term protection for cardiac pacemakers and defibrillators. This tackles a huge market estimated to be worth around 600 million. Elutia is aiming to introduce CanGaroo RM to the market in the first half of 2024.
Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Standard Of Care:
Medtronic (NYSE: MDT) stands as the exclusive provider of the antibiotic envelope within the current market. This envelope is crafted using synthetic mesh infused with antibiotics. Back in 2014, Medtronic acquired this technology, making a strategic investment of up to $200 million. Primarily intended for Cardiac Implantable Electronic Device (CIED) revision procedures, this product boasts estimated annual sales in the range of $250 to $300 million.
However, despite its market presence and revenue generation, the Medtronic antibiotic envelope has notable limitations. While it effectively combats infections, its synthetic composition renders it less effective in supporting wound healing. Moreover, it poses challenges in accommodating larger devices like Subcutaneous Implantable Defibrillators (SCID).
Drug-eluting biomatrix (DEB):
Drug-eluting biomatrix (DEB) involves a specialized approach to drug delivery using a biomatrix as a carrier or platform. In simple terms, it’s a technique where a biomaterial matrix, often a biocompatible polymer or similar substance, is used to release drugs in a controlled and targeted manner.
The biomatrix acts as a support structure that can hold and gradually release drugs or therapeutic agents at a specific site in the body, typically over an extended period. This is particularly useful in medical applications where a localized and sustained delivery of medication is necessary.
For instance, in the context of Elutia’s CanGaroo RM, a biomatrix incorporating antibiotics rifampin and minocycline is used to provide prolonged protection for cardiac pacemakers and defibrillators. The biomatrix slowly releases these antibiotics at the surgical site, preventing infections and promoting healing.
DEB technology is gaining traction because it enhances treatment efficiency by ensuring the drug is delivered directly to the target area, minimizing side effects, and optimizing therapeutic outcomes. It’s a promising approach in the field of medical advancements, especially in areas like cardiology, oncology, and orthopedics.
Post-mastectomy Breast Reconstruction:
On top of this, the company also has plans to develop an RM version of its SimpliDerm biomatrix tailored for breast reconstruction procedures. The rate of infections after this surgery is quite high, more than 10%, highlighting a big medical need in a market valued at over $500 million. Elutia is stepping up to address this issue by developing SimpliDerm® RM, which incorporates their unique DEB technology. The funds raised through the private investment round (PIPE) and the sale of the Orthobiologics business unit will not only boost Elutia’s efforts in advancing their drug-eluting biomatrix products for the cardiac pacemaker and defibrillator market, but also for post-mastectomy breast reconstruction.
What’s next:
As mentioned earlier, their biomatrix platform serves two major markets. CanGaroo RM, their upcoming product, is slated for a 1H of 2024 market release and is poised to be a pioneer in a $600 million market. Furthermore, their SimpliDerm RM product utilizes the same proprietary antibiotic-eluting technology found in CanGaroo RM, which serves a 1.6B market according to their presentation deck. They aim to secure an IDE by Q4 2024, and upon achieving these milestones, they plan to venture into neurostimulator markets, particularly in pain management, to further drive their growth.
We will update you on ELUT when more details emerge, subscribe to Microcapdaily to follow along!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.